Patents by Inventor Kathleen B. Calati

Kathleen B. Calati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220289785
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: July 28, 2021
    Publication date: September 15, 2022
    Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
  • Patent number: 11117917
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: September 14, 2021
    Assignee: Sirna Therapeutics, Inc.
    Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
  • Patent number: 10532068
    Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: January 14, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffrey G. Aaronson, Weimin Wang
  • Publication number: 20190153016
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: February 5, 2019
    Publication date: May 23, 2019
    Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
  • Patent number: 10239957
    Abstract: Disclosed herein is a peptide containing conjugate comprising (P)c-(L)d-(G)e, wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L)a-(G)b, wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
  • Patent number: 10221205
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: March 5, 2019
    Assignee: Sirna Therapeutics, Inc.
    Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
  • Publication number: 20190015442
    Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurance of P is independently selected from Table 2; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
    Type: Application
    Filed: May 8, 2018
    Publication date: January 17, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffrey G. Aaronson, Weimin Wang
  • Patent number: 10010562
    Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: July 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffrey G. Aaronson, Weimin Wang
  • Publication number: 20180079769
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: November 8, 2017
    Publication date: March 22, 2018
    Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
  • Patent number: 9840531
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: December 12, 2017
    Assignee: Sirna Therapeutics, Inc.
    Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
  • Publication number: 20170306324
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: April 7, 2017
    Publication date: October 26, 2017
    Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
  • Publication number: 20170189441
    Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
    Type: Application
    Filed: November 3, 2014
    Publication date: July 6, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
  • Patent number: 9655976
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: May 23, 2017
    Assignee: Sirna Therapeutics, Inc.
    Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
  • Publication number: 20170081425
    Abstract: Disclosed herein is a peptide containing conjugate comprising (P)c-(L)d-(G)e, wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L)a-(G)b, wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.
    Type: Application
    Filed: November 3, 2014
    Publication date: March 23, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
  • Publication number: 20150246133
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: May 1, 2013
    Publication date: September 3, 2015
    Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk